The Latest

• 

  Lupus R&D has come a long way, and the next breakthroughs could come from cell therapy

  But the therapies will need to prove their worth in the clinic over the next few years.

  Biotech

• 

  AI is already delivering pharma value — and not just in drug discovery

  While AI-generated drugs grab headlines, the technology is making more of an impact doing less “glamorous” tasks.

  Biotech

• 

  RFK Jr.’s autism fixation hearkens back to his stance on vaccines

  The head of HHS is seeking the “root causes” of autism spectrum disorder through a large government research project.

  Leadership

• 

  Alnylam keeps pushing the rare disease paradigm as RNAi promises even wider indications

  With another rare disease approval under its belt, Alnylam is still revving up the R&D engines for new indications.

  Biotech

• 

  Prasad’s FDA appointment pressures cell and gene therapy stocks

  A vocal opponent of his predecessor Peter Marks, Dr. Vinay Prasad will now lead the office tasked with reviewing some genetic medicines, adding more uncertainty to an already struggling field of research.

  Biotech

• 

  With TV ads under threat, here’s how pharma can leverage social media

  RFK Jr.’s plan to ban TV advertising may shift more marketing attention to online platforms.

  Commercialization

• 

  On tariffs and pricing, Big Pharma CEOs are waiting out the storm while planning for the worst

  Chief executives at the largest drugmakers in the world are confident tariffs and pricing measures won’t be a major problem. But they’re still poised for change.

  Leadership

• 

  After an up and down year, pharma’s R&D landscape is shifting again

  While clinical trial funding was up, deal-making was down, and new uncertainties are coming into the picture.

  Biotech

• 

  With compounders out of the way, Lilly and Novo go after each other

  The two obesity leaders are pulling on all levers to stay on top of the market.

  Commercialization

• 

  Is pharma ready to let go of animal testing?

  Regulators have signaled their willingness to embrace alternative tests and guide the industry in new directions.  

  Biotech

• 

  Q&A

  Can real-world evidence bear some of the burden left by NIH cuts? This CEO sees an opportunity.

  Turmoil at the NIH has led to handwringing among researchers and drugmakers who rely on public funding. 

  Biotech

• 

  J&J scores FDA OK for immune drug touted as future blockbuster

  The company has predicted that Imaavy — now approved for myasthenia gravis — could eventually earn more than $5 billion in annual sales at its peak.

  Pharma

• 

  US backlash against mRNA vaccines could hinder scientific progress

  U.S. health agencies are taking the fight to vaccine and mRNA research, which could have lasting repercussions on medical and scientific advancements.

  Biotech

• 

  Is the FDA headed for a major reorganization?

  A leaked document revealed details about changes that could impact how the agency operates, but recent comments from FDA Commissioner Dr. Marty Makary have muddied the picture. 

  Pharma

• 

  Flagship’s latest venture reflects more than 25 years of leaping into the unknown

  A new AI-based company launched by the prolific venture capital firm Flagship Pioneering marks another platform approach in forward-thinking early science.

  Biotech

• 

  FDA’s job cuts paint mixed picture for drugmakers’ R&D plans

  After a 20% cut to the FDA’s workforce, biotechs and pharmas are bracing for delays. But the impacts won’t be consistent.

  Pharma

• 

  What’s being cut at NIH

  A look at the government’s far-reaching rollback in research grants so far.

  Biotech

• 

  Will Cobenfy’s clinical stumble derail a once-predicted rise?

  BMS hopes to broaden the applications for the new schizophrenia drug into areas such as Alzheimer’s disease.

  Pharma

• 

  Trump reveals pharma reform priorities in drug pricing executive order

  The order takes aim at fixing the IRA’s “pill penalty,” as well as PBM reform and other attempts to lower drug prices.  

  Pharma

• 

  Beyond the drug: Closing the knowledge gap for injectable diabetes meds

  As the diabetes and weight loss market booms, more collaboration between pharma and medtech could help patients get the most out of injectable drugs. 

  Patient

• 

  Genetic breakthroughs could point pharma to a long COVID drug

  The discoveries also hold potential benefits for patients with other conditions, such as chronic fatigue syndrome.

  Patient

• 

  Can anything threaten Novo and Lilly’s obesity market dominance?

  Five GLP-1 products will collectively bring in $470 billion by 2030, and the market leaders are working to hold back competition.

  Commercialization

• 

  How a scrapped Pfizer drug became a winner for SpringWorks

  SpringWorks Therapeutics and the Children’s Tumor Foundation salvaged a shelved asset for neurofibromatosis and got it over the regulatory finish line.

  Biotech

• 

  A big moment is coming for psychedelics

  Compass Pathways expects to publish the first phase 3 results from a large-scale, psilocybin drug trial by the end of this quarter.

  Biotech

• 

  Novartis scores NFL deal to tackle health outcomes

  The non-traditional marketing approach comes amid a potential crackdown on TV drug ads. 

  Commercialization